Business

The Cures 2.0 Act: Transformative Investment in Early-Stage Biopharmaceutical Development & Commercialization

A bill that provides important frameworks for breakthrough products in the next three to five years

Anna Du
Anna Du
Nov 24 · 7 min read

You may not have noticed the recent Cures 2.0 Act introduced to Congress by two U.S. Representatives, Diana DeGette (D-CO) and Fred Upton (R-MI).

The tone and tenor of national life sciences policy matters.

A path to market for early-stage research

Who are the direct competitors?

Is there market interest?

What is the time and cost to market?

What is the appropriate IP strategy?

Has a business model been defined?

What channels of distribution are important?

To be clear, biopharmaceutical research does not need commercialization to justify quality, applicability, or impact.

Photo by Louis Reed on Unsplash

What ARPA-H may look like structurally

True breakthrough criteria in the near-term

Photo by Patrick Perkins on Unsplash

Potential use cases

Diseases with standard of care limitations

Multi-indication biopharmaceutical modalities

New cost-sensitive, patient-centered clinical paradigms

Photo by Marcelo Leal on Unsplash

The future of Cures 2.0

Follow Bioeconomy.XYZ, in order to learn more about all the ways biotech, is shaping the world around us.

Bioeconomy.XYZ

Innovation for the Bioeconomy

Bioeconomy.XYZ

The Medium publication for biotechnology and everyone involved in the revolution. The best brought to you by the brightest.

Anna Du

Written by

Anna Du

Healthcare BD at University of California, San Francisco. Life sciences enthusiast. Currently writing about early-stage biopharma.

Bioeconomy.XYZ

The Medium publication for biotechnology and everyone involved in the revolution. The best brought to you by the brightest.